Bausch + Lomb price target raised to $19 from $18 at Barclays
Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...
Healio4d
Bausch + Lomb acquires Whitecap Biosciences
Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...
Bausch + Lomb Buys Pharma Company Whitecap Biosciences
Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...
ophthalmologytimes5d
City Therapeutics and Bausch + Lomb partner on geographic atrophy treatment candidate
City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...
Bausch + Lomb unit acquires Whitecap Biosciences, terms undisclosed
Bausch + Lomb (BLCO) announced an affiliate has acquired Whitecap Biosciences which is currently developing two innovative therapies for ...
New Jersey Business8d
Character Biosciences Collaborating with Bausch + Lomb
Jersey City-based Character Biosciences has announced a collaboration with Bausch + Lomb to develop innovative treatments for ...
TMCnet11d
Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine
Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative ...
Joplin Globe11d
City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy
City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced that it has entered into a strategic collaboration ...